AK and miltefosine

Three weeks after treatment with oral miltefosine offers promising hope for patients with AK. Miltefosine is not yet approved for AK but has received orphan drug designation.

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO